جستجوی استاد راهنمای دانشگاهی

• Muscle Metabolism
• Insulin Resistance
• Diabetes Research
• +۱۱ مورد دیگر

Dr. Richard Mackenzie is a Reader in Insulin Resistance & Metabolism at the School of Life and Health Sciences, University of Roehampton , where he also serves as Research Director for the Sport & Exercise Science Research Group. He previously held a Senior Lecturer position at the University of Westminster (2008-2015) and was a Research Physiologist at the University of Brighton (2005-2008). His research focuses on metabolic regulation in health and disease states, particularly type 2 diabetes and elite athlete physiology. Dr. Mackenzie's work explores: Muscle metabolism in health, obesity, and diabetes Role of obesity in insulin resistance and metabolic disease Hematological and muscular adaptations to acute hypoxia Akt/PKB inhibition via IP6K1 and IP7 in insulin signaling Myostatin signaling and skeletal muscle protein turnover His peer-reviewed publications examine topics ranging from hypoxia-induced metabolic changes to dietary interventions for glucose homeostasis. Dr. Mackenzie also engages in media appearances (BBC Radio 4, Horizon documentaries) and consultancy work for metabolic device development (e.g., Mediwise glucose-monitoring technology).

• Metabolism
• Molecular Medicine
• Exercise Physiology
• +۵ مورد دیگر

Curtis Hughey serves as Assistant Professor of Medicine within the Division of Molecular Medicine, conducting interdisciplinary research at the nexus of metabolism, molecular physiology, and metabolic disease pathogenesis. His work bridges basic science with clinical implications through innovative methodologies in metabolomics and metabolic flux analysis. His research program critically examines: Mitochondrial metabolism in liver, skeletal muscle, and placental tissues Exercise-induced metabolic adaptations and dysregulation in obesity NAFLD pathogenesis mechanisms involving lipotoxicity and inflammation Metabolomic biomarker discovery for metabolic diseases Regulation of gluconeogenesis and glucose homeostasis Analysis of Hughey's recent publications (2019-2023) reveals a dominant focus on tissue-specific metabolic crosstalk, particularly hepatic-muscle interactions during exercise and disease states. His work consistently employs advanced techniques including 2 H/ 13 C flux analysis, untargeted metabolomics, and genetically modified mouse models to dissect molecular mechanisms. Recurring themes include the dual roles of metabolic enzymes (e.g., PEPCK, pyruvate carboxylase), the impact of dietary interventions on liver metabolism, and the discovery of analytical artifacts in lipidomics that could confound biomarker research.

• Network Biology
• Computational Systems Medicine
• Proteomics
• +۴ مورد دیگر

Jörg Menche holds a full Professor position (Univ.-Prof.) at the University of Vienna, with dual appointments in the Faculty of Mathematics, Department of Mathematics, and Max Perutz Labs, Department of Structural and Computational Biology. His work bridges mathematical modeling and biomedical research through network-based approaches to complex disease mechanisms. Primary research interests include Network Biology, Computational Systems Medicine, and Immunometabolism, with specific focus on proteomic signatures in neuropathic pain, metabolic reprogramming in obesity, and autoimmunity networks. He develops innovative computational tools like VRNetzer for virtual reality network analysis and BioProfiling.jl for high-content imaging data integration, targeting intersections between metabolism, immunity, and environmental exposures. Recent publications (2019-2024) reveal a dominant trend in multi-omics network medicine, particularly in autoimmunity (AutoCore framework), cardiometabolic diseases, and rare genetic disorders. His work demonstrates exceptional translational impact, with multiple papers highlighted by news outlets and patents (e.g., 3 patents referencing 2021 research). While the text indicates involvement in one project (2016) and 13 activities, grant specifics and student mentoring details remain undisclosed. His collaborative network spans immunology, neuroscience, and toxicology, evidenced by co-authorships with clinical and computational teams. Menche operates within Max Perutz Labs, a premier molecular biology research center in Vienna. His team integrates computational biologists, cell biologists, and clinicians to develop network cartography methods for disease module identification, with strong emphasis on virtual reality interfaces and multi-omics validation.

• Immunology
• Cardiology
• Molecular Biology
• +۲ مورد دیگر

Dr. Karim Bennaceur is a researcher at Newcastle University , focusing on the intersection of immunology and cardiovascular medicine. His work explores immune cell dynamics, telomerase mechanisms, and inflammatory pathways in myocardial infarction and ischemic injury. Key collaborations include studies on TGF-β1 mimics, telomerase activation, and CMV-seropositivity impacts on cardiac recovery. Research spans immunology , cardiology , and molecular biology , with a focus on lymphocyte kinetics, chemokine signaling, and telomere maintenance. His publications highlight clinical trials in elderly patients and mechanistic insights into T cell proliferation and atherosclerosis.

Kevin Pruittمشاهده پروفایل

دانشیار

• Wnt signaling
• Dishevelled proteins
• Cancer epigenetics
• +۴ مورد دیگر

Kevin Pruitt is an Associate Professor in the Department of Pharmacology at the University of North Carolina School of Medicine . His research bridges cancer epigenetics , Wnt signaling , and aromatase regulation , with a focus on understanding how epigenetic enzymes modulate oncogenic pathways and tumor-immune interactions. Key projects include: Elucidating epigenetic drivers in cancer progression and immune evasion Investigating nuclear and cytosolic roles of Dishevelled proteins in Wnt signaling Decoding mechanisms of aromatase dysregulation in breast cancer Research Trends : Recent publications highlight his work on the tumor microenvironment (e.g., cryoablation-induced immune changes, Sertoli cell immunoregulation) and nuclear Wnt signaling (e.g., Dishevelled localization, transcriptional targets). His studies often intersect with epigenetic therapies and hormone-sensitive cancers . Education & Affiliation : While specific educational details are not provided, his academic career spans institutions like LSU Health Sciences Center and UNC Chapel Hill. He leads the Pruitt Lab , focusing on epigenetic and Wnt pathway interactions. Collaborative Networks : Frequent co-authors include experts in cancer biology, immunology, and molecular genetics, such as Drs. Layeequr Rahman, Suresh Ramachandran, and Sandra Almodovar.

Narasimman Gurusamyمشاهده پروفایل

استادیار

• Epigenetics
• Cardiac diseases
• non-coding RNA
• +۳ مورد دیگر

Dr. Narasimman Gurusamy is an Assistant Professor at the Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, specializing in Pharmaceutical Sciences. He holds a Ph.D. in Pharmaceutical Sciences from Niigata University of Pharmacy and Applied Life Sciences (Japan) and completed postdoctoral training at UConn Health Center, Harvard Medical School, and University of Tennessee Health Science Center. Education: M.Pharm (Tamil Nadu Dr. MGR Medical University, India), Ph.D. (Niigata University, Japan) Research Focus: Epigenetic mechanisms in cardiac diseases, non-coding RNA regulation, exosome therapy, stem cell biology, and gene-environment interactions His work explores how long non-coding RNAs and epigenetic modifiers influence cardiac repair, particularly through induced mesenchymal stem cells and their exosomal signaling . Current projects investigate dietary and environmental impacts on epigenetic changes in the heart. Recent publications highlight advancements in RNA-based therapies and metabolic interventions for cardioprotection. Scientific Awards: American Heart Association Career Development Award, Young Research Scientist Award, Travel Awards Dr. Gurusamy serves as Grant Reviewer for the American Heart Association, Associate Editor for Frontiers in Cardiovascular Medicine , and Vice-Chair for the Communication Committee of the Society for South Asian Heart Research (SAHR). His lab employs in-vitro, in-vivo, and clinical trial approaches, utilizing PCR, ELISA, flow cytometry, and genomic repository analyses.

Joseph R. Testaمشاهده پروفایل

استاد

• Molecular Biology of Mesothelioma
• Cancer Genetics
• Oncogenesis
• +۱۰ مورد دیگر

Joseph R. Testa is a Professor and Senior Member at Fox Chase Cancer Center, where he holds the Carol and Kenneth E. Weg Chair in Human Genetics. He serves as Chief of Genomic Medicine and Director of the Clinical Cytogenomics Laboratory within the Cancer Prevention and Control program. His research is centered on the molecular genetics of malignant mesothelioma and the oncogenic role of the AKT pathway. University: Fox Chase Cancer Center School: Cancer Prevention and Control Department: Genomic Medicine Academic Rank: Professor Dr. Testa’s research focuses on hereditary and somatic mutations in cancer, particularly in mesothelioma. He discovered germline mutations in the BAP1 gene, leading to the identification of the BAP1 tumor predisposition syndrome. His lab uses genetically engineered mouse models to study gene-environment interactions, tumor development, and preclinical drug testing. Key interests include AKT signaling, NF2 inactivation, and inflammation-driven oncogenesis. His work has revealed mechanisms of chemoresistance and potential therapeutic targets such as FAK and RIPK3. His recent publications (2020–2025) reflect a strong focus on molecular mechanisms in mesothelioma, T-cell lymphoma, and cancer immunology. Trends include the use of transgenic models, epigenetic regulation, and pathway crosstalk (e.g., Wnt, cholesterol synthesis). He actively explores immunogenicity, targeted therapy, and synthetic lethality in genetically defined cancers. Scientific awards include: AACR Most-Cited Article (2018) Pioneer Research Award, MARF (2013) Wagner Medal, IMIG (2012) Elected Fellow, AAAS (2012) Landon-AACR Innovator Award (2008) Irving Selikoff Award (1999) Dr. Testa has mentored numerous researchers and leads a multidisciplinary lab team. He has received continuous grant support for studies on mesothelioma genetics and signaling. His lab collaborates internationally, particularly in BAP1 syndrome research. He is an editorial board member for multiple journals and has served on the NCI Board of Scientific Counselors. His work bridges basic discovery and clinical translation, influencing genetic testing and therapeutic strategies. The Testa Lab includes key personnel such as Yuwaraj Kadariya, Eleonora Sementino, Ujjawal Shrestha, and Yinfei Tan, focusing on mouse models, cytogenetics, and molecular mechanisms of tumorigenesis.

Aeson Changمشاهده پروفایل

مدرس

• Breast Cancer
• Cancer Metastasis
• Sympathetic Nervous System
• +۷ مورد دیگر

Aeson Chang is a Lecturer in the Drug Discovery Biology department at Monash University, where he conducts research at the intersection of pharmacology and cancer biology. His work is deeply rooted in understanding how the sympathetic nervous system influences breast cancer progression and metastasis. His research interests center on breast cancer metastasis , drug repurposing for chemotherapy enhancement , and the role of biobehavioral and neuroimmune pathways in cancer outcomes. He investigates how beta-blockers can improve responses to anthracycline chemotherapy, particularly in aggressive triple-negative breast cancer, and how circadian disruption affects cancer-related inflammation. The recent publications highlight a strong trend in translational oncology, combining preclinical models with epidemiological data to explore how commonly used drugs and lifestyle factors influence cancer progression. His work spans molecular pharmacology, systems physiology, and population health, aiming to bridge laboratory findings with clinical applications. Dr. Chang has not been mentioned to have received any specific scientific awards in the provided text. While there is no explicit mention of student supervision or grant funding in the provided content, his active collaboration with leading researchers such as Erica Sloan suggests involvement in funded research programs and mentorship within a team-based scientific environment. His research is conducted within the Drug Discovery Biology theme at Monash University, a multidisciplinary environment focused on identifying novel therapeutic strategies for complex diseases including cancer.

Inez Schoenmakersمشاهده پروفایل

مدرس ارشد

• Bone Health
• Vitamin D Metabolism
• Calcium and Phosphate Metabolism
• +۷ مورد دیگر

Inez Schoenmakers is a Senior Lecturer at the Norwich Medical School, Faculty of Medicine and Health Sciences, University of East Anglia, UK. She joined UEA in 2016 after working at MRC-Human Nutrition Research in Cambridge. Her work spans clinical and nutritional research with a focus on bone health, vitamin D metabolism, and mineral homeostasis. Education: BSc in Health Sciences, University of Maastricht, The Netherlands MSc in Health Sciences/Medical Biology, University of Maastricht, The Netherlands PhD, Utrecht University, The Netherlands Her research investigates the metabolic underpinnings of bone health across the lifespan, particularly in the context of aging, kidney function, nutrition, ethnicity, and genetic factors. She utilizes RCTs, stable isotope methods, and observational studies in both healthy individuals and patient groups. Her work is highly relevant to conditions involving the renal-bone axis and metabolic bone diseases. The trends in her recent publications highlight a strong focus on vitamin D’s role in bone and mineral metabolism, especially in renal impairment and aging populations. Her work spans clinical observations, pharmacological analysis, and public health implications, appearing in top journals such as Nature Reviews Endocrinology , JAMA , and Age and Ageing . Professional Memberships: American Society for Bone and Mineral Research Bone Research Society She has received research funding from the Medical Research Council, Biotechnology and Biological Sciences Research Council, Academy of Medical Sciences, and Arthritis Research UK. She also provides expert consultation for collaborative projects and governmental bodies, including the WHO. She is currently supervising PhD projects on dietary strategies to protect bone health in renal disease and is accepting new PhD students. She is an active member of research networks involving musculoskeletal medicine, nutrition, and preventive medicine, and contributes to public understanding through media engagement on vitamin D and bone health.

• Chronic Rhinosinusitis
• Olfactory Dysfunction
• Vitamin D Metabolism
• +۵ مورد دیگر

Jennifer K. Mulligan is an Associate Professor in the Department of Otolaryngology – Head & Neck Surgery at the University of Florida. She holds multiple leadership roles including Vice Chair for Research, Co-Director of the UF Health Smell Disorders Program, and Director of Resident Research Education. Her academic work focuses on the immunopathogenesis of chronic rhinosinusitis (CRS) and olfactory dysfunction, with a particular interest in vitamin D metabolism, complement system regulation, and epithelial cell biology. Her research employs experimental models and clinical studies to investigate mechanisms underlying sinonasal inflammation and olfactory impairment. Notable contributions include elucidating roles of vitamin D3 in modulating immune responses and epithelial function, and developing biomarker-based endotyping strategies for CRS subtypes. She has pioneered nasal mucus proteomics and olfactory cleft analysis to identify novel therapeutic targets. Dr. Mulligan's grant portfolio includes NIH-funded projects on vitamin D modulation of CRS inflammation, immune responses to SARS-CoV-2 in upper airways, and biologic therapies for nasal polyposis. She leads clinical trials evaluating treatments like dupilumab for smell recovery. Over 100 peer-reviewed publications span immunology, otolaryngology, and translational research methodologies. Her teaching activities include instructing the GMS6847 course on translational research principles. She mentors residents and fellows in surgical research through structured educational programs. Active collaborations involve immunologists, bioengineers, and clinical researchers across multiple institutions.

• Autophagy
• Mitophagy
• Retinal Degeneration
• +۷ مورد دیگر

Patricia Boya is a Full Professor in the Department of Medicine at the University of Fribourg, within the Faculty of Mathematics, Natural Sciences and Medicine. She is a leading researcher in autophagy, mitophagy, and lysosomal biology, with a focus on retinal and neurodegenerative diseases. Her research interests center on the molecular mechanisms of autophagy and mitophagy, particularly their roles in retinal health, aging, neurodegeneration, and cell death. She investigates how mitochondrial dynamics, lysosomal function, and autophagic flux contribute to diseases such as retinitis pigmentosa, glaucoma, ALS, and Parkinson’s. Her work combines molecular biology, cell imaging, and preclinical models to uncover therapeutic targets. The analysis of her recent publications reveals a strong focus on mitophagy regulation, neuroinflammation (especially via the cGAS/STING pathway), and the development of neuroprotective compounds. She has contributed to high-impact reviews and guidelines in autophagy research, and her work spans fundamental mechanisms to translational applications. She is actively involved in scientific leadership, including the "Women in Autophagy" initiative to promote gender equity in science and the "DRIVE" international PhD training program in autophagy. Dr. Boya has published over 150 articles in top journals including Nature , Nature Communications , Autophagy , and Cell Death & Disease . Her work is highly collaborative, involving interdisciplinary teams across Europe. She leads a research group focused on cellular recycling mechanisms and their implications for vision and aging, contributing significantly to the understanding of autophagy in health and disease.

• Developmental Neurobiology
• Neurodegeneration
• Lab-on-Chip Technology
• +۴ مورد دیگر

José Antonio Del Río Fernández is a distinguished Professor and Group Leader at the Institute for Bioengineering of Catalonia (IBEC) , where he directs the Molecular and Cellular Neurobiotechnology group. His work bridges developmental neurobiology , neurodegeneration , and lab-on-chip technology , focusing on diseases like Alzheimer's and Parkinson's . He has been active in academic research for over 30 years, previously affiliated with institutions such as the University of Barcelona , Frankfurt University , and Imperial College London . Education : PhD , University of Barcelona (1994) Research Interests center on neurodegenerative disease mechanisms , particularly the spreading of tau and α-synuclein in conditions like Alzheimer's and Parkinson's, and axon regeneration after CNS injury. His group pioneers lab-on-chip devices to model neurobiological processes and test regenerative therapies. Collaborations span institutions such as Imperial College , i3A, Zaragoza , and Biodonostia Hospital . Scientific Contributions include over 170 publications, with a H-index of 48 (Web of Science) and 55 (Google Scholar), and significant advancements in understanding prion protein interactions in neurodegeneration. His recent work explores optogenetics for axon regeneration and multitarget compounds for Alzheimer's therapy. He has mentored 24 PhD students , 26 Master's students , and 15 postdoctoral fellows , reflecting a strong commitment to academic training. Scientific Awards : Fundación Francisco Cobos CSIC Award (2001) Generalitat of Catalunya Award of Young Researcher (2003) Research Trends demonstrate a focus on neurodegenerative disease mechanisms , lab-on-chip platforms , and axon regeneration strategies . His collaborations with institutions like Imperial College London and University of Zaragoza highlight interdisciplinary approaches integrating biomaterials , optogenetics , and computational modeling .

Suzaynn Schickمشاهده پروفایل

پژوهشگر

• Air Pollution
• Environmental Health
• Tobacco Smoke Toxicity
• +۴ مورد دیگر

Suzaynn Schick is a prominent researcher at the University of California San Francisco (UCSF), affiliated with the UCSF Center for Tobacco Control Research and Education, the Helen Diller Family Comprehensive Cancer Center, and the California Thirdhand Smoke Consortium. Her work focuses on the chemistry and toxicity of tobacco and cannabis smoke, with particular emphasis on thirdhand smoke as a long-term environmental pollutant. Education: B.S. in Cell and Molecular Biology (University of Washington, 1986-1989) Ph.D. in Biomedical Science (UCSF, 1991-2001) Postdoctoral studies in Public Health (UCSF, 2002-2006) and Inhalation Toxicology (UCSF, Feb 2006-Sept 2007) Schick's research explores how smoke pollutants contribute to cardiovascular and respiratory diseases. Her groundbreaking studies demonstrate that thirdhand smoke—a residue of oils and waxes on surfaces—remains carcinogenic long after active smoking ceases, challenging conventional assumptions about secondhand smoke risks. Recent publications highlight her work on thirdhand smoke's role in gastric tumor development, endothelial dysfunction from cannabis and cigarette aerosols, and the persistence of toxins in indoor environments. Her studies span molecular toxicology, air quality analysis, and public health policy implications. Scientific Awards: National Science Foundation Predoctoral Fellowship (1991) Schick's funded projects include investigations into melanin's role in thirdhand smoke absorption and environmental pollutant measurement. She advocates for stronger protections against involuntary smoke exposure through policy engagement and interdisciplinary collaboration.

• Interstitial Lung Disease
• Pulmonary Fibrosis
• Lung Injury Mechanisms
• +۳ مورد دیگر

Martin Rainer Kolb is a Professor of Medicine at McMaster University's Faculty of Health Sciences, specializing in Interstitial Lung Diseases (ILD) and General Respirology at St. Joseph's Healthcare Hamilton. He serves as Section Editor for ILD in the European Respiratory Journal, one of the top journals in respiratory medicine with an impact factor of 24.9, having previously served as Chief Editor. Dr. Kolb's research focuses on mechanisms of lung injury, repair and fibrosis, particularly in Idiopathic Pulmonary Fibrosis (IPF). His work spans pre-clinical studies of disease mechanisms, efficacy of novel drugs, and biomarker development for lung fibrosis. He actively leads international and national ILD clinical trials as Principal Investigator and Steering Committee member. His scholarly output shows a strong focus on progressive pulmonary fibrosis, with recent publications examining CT patterns, biomarkers, macrophage polarization, drug treatments like nintedanib, and patient pathways in ILD. His work demonstrates a consistent trajectory from basic mechanisms to clinical applications in fibrotic lung diseases. Dr. Kolb has received significant recognition including election to the Canadian Academy of Health Sciences and awards from the Parker B. Francis Families Foundation, Canadian Institute for Health Research, and the National Institute for Health. Parker B. Francis Families Foundation Award Canadian Institute for Health Research Award National Institute for Health Award Fellow of the Canadian Academy of Health Sciences With over 300 peer-reviewed publications, Dr. Kolb maintains an active research program that bridges basic science and clinical applications in pulmonary fibrosis. His leadership extends to journal editorial roles and multicenter clinical trials, significantly influencing the field of interstitial lung disease research and treatment.

Marceline Côtéمشاهده پروفایل

استاد

• Host-pathogen interactions
• Emerging viruses
• Antiviral therapeutics
• +۳ مورد دیگر

Dr. Marceline Côté is a Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa's Faculty of Medicine. She serves as Director of the Centre for Infection, Immunity and Inflammation (CI3), where she leads research on host-pathogen interactions during emerging viral infections. BSc from Université de Sherbrooke (2004) PhD from McGill University (2009) Postdoctoral Fellowship at Brigham and Women's Hospital & Harvard Medical School Her research focuses on identifying host proteins critical for viral infection by filoviruses (Ebola, Marburg), arenaviruses (Lassa fever), and coronaviruses (SARS-CoV, SARS-CoV-2, MERS). Using virological, chemical biology, and genetic approaches, she investigates viral entry pathways and develops antiviral therapeutics targeting host factors. Recent publications highlight her work on SARS-CoV-2 entry mechanisms, filovirus trafficking, and diacylglycerol kinase inhibition as an antiviral strategy. Her lab explores how pathogens exploit endosomal phosphoinositides and intracellular vesicular trafficking systems.